Novo Nordisk Concedes 'Jury Still Out' on CagriSema as Retatrutide Sets a High Bar at ADA 2026

The American Diabetes Association's 86th Scientific Sessions have become an inflection point in the obesity drug arms race — and for Novo Nordisk, the comparisons to Eli Lilly's retatrutide are impossible to ignore. In a candid moment at the conference, Martin Holst Lange, Novo Nordisk's Executive Vice President of Development, acknowledged that the "jury is still out" on whether CagriSema — the company's amylin-based combination therapy — can match retatrutide's best-in-class weight loss results. The statement, [reported by Fierce Biotech](https://www.fiercebiotech.com/), reflects the pressure Novo Nordisk faces as it attempts to defend its position in a market it pioneered with semaglutide (Ozempic/Wegovy). Retatrutide's TRIUMPH-1 results — showing 28.3% average weight loss at the highest dose — have reset expectations for what pharmacologic obesity treatment can achieve, and every competitor is now measured against that benchmark. ## CagriSema's positioning: safety over maximal efficacy Lange's argument for CagriSema rests not on matching retatrutide's efficacy pound-for-pound, but on offering a different risk-benefit profile. CagriSema combines semaglutide (a GLP-1 receptor agonist) with cagrilintide (an amylin analogue), targeting two pathways rather than retatrutide's three (GIP, GLP-1, and glucagon). The amylin component, Novo argues, may produce fewer gastrointestinal side effects and a lower heart rate increase — two tolerability concerns observed with retatrutide in clinical trials. "Not every patient needs maximum weight loss," Lange told Fierce Biotech, suggesting that a drug with a gentler side-effect profile could capture a substantial share of the market — particularly among patients who discontinue treatment due to tolerability issues. This is a strategic pivot: if you cannot win on efficacy, win on tolerability and real-world persistence. ## The glucagon question At the heart of the retatrutide-versus-CagriSema debate is the glucagon receptor — the third target in retatrutide's mechanism and the one that distinguishes it from all other late-stage obesity candidates. Glucagon receptor activation is thought to increase energy expenditure (calories burned) in addition to suppressing appetite, potentially explaining retatrutide's superior weight loss. But glucagon activation also raises questions. Elevated glucagon signalling has been associated with increased heart rate and, in theoretical models, could affect glucose counterregulation. Lange's comments suggest Novo Nordisk is betting that avoiding glucagon agonism will prove to be a safety advantage — one that regulators, prescribers, and patients will value. Lilly, for its part, has pointed to the comprehensive safety data across the TRIUMPH and TRANSCEND programs as evidence that retatrutide's risk profile is manageable and consistent with the GLP-1 class. At ADA, the company presented data showing that retatrutide's heart rate increases were modest (2-4 beats per minute) and plateaued early in treatment without progressive escalation. ## Canadian Context For Canadians, this competitive dynamic matters for several reasons: **Market access and pricing:** If both retatrutide and CagriSema reach the Canadian market — each backed by a different pharmaceutical giant — competition could drive more favourable pricing negotiations with the Patented Medicine Prices Review Board (PMPRB) and provincial drug plans. Canada's single-payer system makes it a price-sensitive market, and having two viable advanced obesity medications could improve the odds of public formulary coverage. **Clinical choice for physicians:** Canadian endocrinologists and obesity medicine specialists, a relatively small but growing community, would benefit from having multiple therapeutic options with different mechanisms and side-effect profiles. A patient who cannot tolerate retatrutide's glucagon-mediated effects might do well on CagriSema, and vice versa. **Regulatory timeline:** While retatrutide is further ahead in development (Phase 3 data already presented), CagriSema's progress through trials will influence Health Canada's assessment of the overall therapeutic class. A robust competitive pipeline signals to regulators that obesity pharmacotherapy is maturing. **Canadian clinical trial participation:** Novo Nordisk has a significant presence in Canada, operating clinical trial sites for its metabolic portfolio. If CagriSema trials expand to Canadian sites, it would offer another avenue for Canadian patients to access novel obesity treatments through the clinical trial pathway. ## The bigger picture The Lange comments reflect a market reality: retatrutide has set the bar, and every competitor must now articulate a clear value proposition relative to it. Novo Nordisk's bet on CagriSema as a more tolerable option is a legitimate strategy — one that echoes earlier dynamics in the statin market, where not every patient needed the most potent cholesterol-lowering agent. But history also suggests that in obesity treatment, where efficacy has been historically modest, a drug that delivers meaningfully better results can reshape prescribing patterns faster than safety nuance arguments can defend market share. Retatrutide's nearly 30% weight loss is in a different category than anything previously available. For patients, the real winners are the millions of Canadians living with obesity who may soon have multiple advanced treatment options where previously there were few. The question is not whether retatrutide or CagriSema is "better" in absolute terms — it is which drug is right for which patient, and whether Canada's healthcare system will be ready to deliver either one when the time comes. ## Sources - [Fierce Biotech — "ADA: Novo's Lange says 'jury still out' on CagriSema amid tough retatrutide comparisons" (June 10, 2026)](https://www.fiercebiotech.com/) - [ClinicalTrials.gov — TRIUMPH-1 (NCT05929066)](https://clinicaltrials.gov/study/NCT05929066) - [Patented Medicine Prices Review Board — Guidelines](https://www.canada.ca/en/patented-medicine-prices-review.html) --- *This article provides educational analysis of publicly reported information. Retatrutide and CagriSema are investigational drugs not yet approved by Health Canada. Always consult a healthcare provider for medical advice.*